Patrick Keating, MD
Ophthalmology · Lafayette, LANPI 1679864292
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,336 of the $7,365 with a category attached, or 86.0%. 26 manufacturers reported payments, led by Alcon at 32.2% of the total. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 304 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$646
- Oyster Point Pharma, Inc.$449
- Biotissue Holdings Inc.$350
- Glaukos Corporation$270
- plus $2K from 20 others
What the payments were for
- Travel & lodging$88512%
- Food & beverage$6,33686%
- Education$981%
- Entertainment$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 52 | $2,370 |
| AbbVie(2 entities) | 83 | $1,260 |
| Sun Pharmaceutical Industries Inc. | 26 | $646 |
| Oyster Point Pharma, Inc. | 26 | $449 |
| Biotissue Holdings Inc. | 16 | $350 |
| Glaukos Corporation | 6 | $270 |
| Novartis | 19 | $223 |
| Bausch & Lomb Americas Inc. | 12 | $212 |
| Ivantis, Inc | 7 | $184 |
| Mallinckrodt Hospital Products Inc. | 5 | $179 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $168 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $164 |
| Tarsus Pharmaceuticals, Inc. | 8 | $158 |
| Aerie Pharmaceuticals, Inc. | 7 | $123 |
| Dompe US, Inc. | 3 | $91 |
| Sight Sciences, Inc. | 4 | $73 |
| Harrow Eye, LLC | 3 | $68 |
| Carl Zeiss Meditec USA, Inc. | 1 | $61 |
| Shire North American Group Inc | 3 | $57 |
| LKC Technologies, Inc. | 1 | $56 |
| Amgen(2 entities) | 3 | $53 |
| Optos, Inc. | 1 | $46 |
| Eyevance Pharmaceuticals LLC | 3 | $45 |
| Omeros Corporation | 2 | $33 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| NEW World Medical,inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARGOS$885
- Centurion$885
- Clareon$885
- XELPROS$187
- Photrexa Viscous and Photrexa$153
- AcrySof IQ PanOptix$127
- LenSx$107
How this compares
$7,365 in reported general payments places this provider in the 90th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 223 | $242,982 |
| TyrvayaVarenicline Tartrate | 53 | $42,366 |
| RocklatanNetarsudil Mesylat/Latanoprost | 94 | $40,908 |
| XiidraLifitegrast | 48 | $34,662 |
| LumiganBimatoprost | 55 | $30,475 |
| Cyclosporine | 65 | $29,351 |
| CombiganBrimonidine Tartrate/Timolol | 67 | $29,134 |
| RhopressaNetarsudil Mesylate | 29 | $16,964 |
| Latanoprost | 868 | $7,899 |
| Prednisolone Acetate | 261 | $7,738 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $7,433 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 307 | $5,698 |
| Brinzolamide | 15 | $4,098 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 73 | $3,505 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 37 | $3,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,260 | $302,591345 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $123 | $57,873123 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $449 | $42,36653 claims |
| Bausch & Lomb Americas Inc.Xiidra | $212 | $34,66248 claims |
| AlconSimbrinza | $2,370 | $7,43325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Lafayette
- Paul AzarLafayette$8K
- Frederick HallLafayette$8K
- Jonathan JosephLafayette$7K
- Kevin SwanLafayette$6K
- Alexandra SellersLafayette$5K
- Blake WilliamsonBaton Rouge$443K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Wyche ColemanShreveport$35K
- Peter KastlNew Orleans$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.